Please assess the completion status of the following clinical trial:

Trial Title: Studying the Efficiency of the Natural Preparation Rutan in Children in the Treatment of COVID-19, ARVI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Submission of a signed and dated informed consent form (guardian). Declared willingness to comply with all study procedures and accessibility during the study.~Children from 6 to 18 years old. Patients with PCR-confirmed COVID-19 with mild/moderate disease. U07.1. Ability to take oral medications and willingness to adhere to the regimen.~Exclusion Criteria:~Severe form of COVID-19. U07.1. Treatment with another investigational drug. Individual intolerance to the drug. The occurrence of any allergic reactions. Weighting of the general well-being of the patient and the transition to a severe form of the disease.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Target group (Type: EXPERIMENTAL): 201 children 6-18 years old with mild to moderate COVID-19, who were taking Rutan.
- control group (Type: OTHER): 100 children 6-18 years old with mild to moderate COVID-19, who were not taking Rutan.

Based on this trial design, predict the completion outcome and termination type (if applicable).